DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026)
DiaMedica Therapeutics (DMAC) reported Receivables of $244,000 for Q2 2026, up 51.6% from $161,000 a year earlier but down 18.9% from the prior quarter.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026) Analysis & Trends
At the end of FY2025, DiaMedica Therapeutics posted Receivables of $266,000, up 12.2% from FY2024.
- Receivables has a five-year compound annual growth rate of -15.8% (FY2020 to FY2025).
- By year, Receivables came in at $237,000 in FY2024 (-46.1%), $440,000 in FY2023 (+423.8%), $84,000 in FY2022 (-35.4%) and $130,000 in FY2021 (-79.3%).
- Five-year quarterly Receivables spans a low of $57,000 in Q1 2023 and a high of $440,000 in Q4 2023.
- Year over year, Receivables has now increased in each of the last three quarters, with an average decline of 9.4% over the last eight quarters.
- The high point for year-over-year Receivables in five years was Q1 2024 (growth of 600.0%); the low point was Q3 2021 (a decline of 83.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $301,000 (Q1 2026), $266,000 (Q4 2025) and $260,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 15.68 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 5.06 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 2.13 Bn |
| 10 | DiaMedica Therapeutics | 445.97 Mn | 445.97 Mn | - | 244,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 244,000.00 |
| Mar 31, 2026 | 301,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 391,000.00 |
| Mar 31, 2024 | 399,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 310,000.00 |
| Jun 30, 2023 | 188,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 84,000.00 |
| Sep 30, 2022 | 75,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 170,000.00 |
| Dec 31, 2021 | 130,000.00 |
| Sep 30, 2021 | 104,000.00 |
API Access
DiaMedica Therapeutics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=DMAC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "DMAC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=DMAC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();